EGFR and non-small cell lung carcinoma: Nanjo et al. [20] examined the effects of the third-generation EGFR TKI osimertinib in a prospective pilot study including 13 patients with T790M-positive NSCLC LM patients after failure of first- or second-line EGFR TKI.